137 related articles for article (PubMed ID: 12481397)
1. [Dysarthria during irinotecan administration].
Ceccaldi B; Kara F; Mommeja-Marin H; Bègue M; Saint Blancard P; Le Marec E; Hauteville D
Rev Med Interne; 2002 Nov; 23(11):950-1. PubMed ID: 12481397
[No Abstract] [Full Text] [Related]
2. Irinotecan chemotherapy associated with transient dysarthria and aphasia.
De Marco S; Squilloni E; Vigna L; Bertagnolio MF; Sternberg CN
Ann Oncol; 2004 Jul; 15(7):1147-8. PubMed ID: 15205214
[No Abstract] [Full Text] [Related]
3. Irinotecan-induced dysarthria.
Baz DV; Bofill JS; Nogueira JA
J Natl Cancer Inst; 2001 Sep; 93(18):1419-20. PubMed ID: 11562394
[No Abstract] [Full Text] [Related]
4. [A case of sigmoid colon cancer with temporary dysarthria associated with irinotecan].
Sogabe S; Yuki S; Takano H; Kobayashi Y; Nakatsumi H; Sasaki T; Kawamoto Y; Fukushima H; Iwanaga I; Uehata Y; Komatsu Y; Asaka M
Gan To Kagaku Ryoho; 2011 Aug; 38(8):1375-7. PubMed ID: 21829085
[TBL] [Abstract][Full Text] [Related]
5. Dysarthria induced by irinotecan in a patient with colorectal cancer.
Lee KA; Kang HW; Ahn JH; Suk HJ; Kim H
Am J Health Syst Pharm; 2013 Jul; 70(13):1140-3. PubMed ID: 23784161
[TBL] [Abstract][Full Text] [Related]
6. Phlebitis due to irinotecan.
Tas F; Karagol H; Karadeniz A; Topuz E
Clin Oncol (R Coll Radiol); 2003 May; 15(3):167. PubMed ID: 12801060
[No Abstract] [Full Text] [Related]
7. Irinotecan-induced immune thrombocytopenia.
Mirtsching BC; George JN; Aster RH; Curtis BR
Am J Med Sci; 2014 Feb; 347(2):167-9. PubMed ID: 24472819
[No Abstract] [Full Text] [Related]
8. Irinotecan (CPT-11) induced colitis: report of a case and review of Food and Drug Administration MEDWATCH reporting.
Sears S; McNally P; Bachinski MS; Avery R
Gastrointest Endosc; 1999 Dec; 50(6):841-4. PubMed ID: 10570349
[No Abstract] [Full Text] [Related]
9. Irinotecan-induced central nervous system toxicity. Report on two cases and review of the literature.
Hamberg P; De Jong FA; Brandsma D; Verweij J; Sleijfer S
Acta Oncol; 2008; 47(5):974-8. PubMed ID: 17924208
[No Abstract] [Full Text] [Related]
10. Irinotecan-induced central nervous system toxicity: a case report.
Sevilla Garcia I; Rueda A; Alba E
J Natl Cancer Inst; 1999 Apr; 91(7):647. PubMed ID: 10203287
[No Abstract] [Full Text] [Related]
11. Irinotecan and UFT/leucovorin in patients with advanced cancers.
Stevenson JP; Redlinger M; Sun W; Haller D; O'Dwyer PJ
Oncology (Williston Park); 2000 Oct; 14(10 Suppl 9):91-2. PubMed ID: 11098504
[TBL] [Abstract][Full Text] [Related]
12. Pharmacogenetic approach for cancer treatment-tailored medicine in practice.
Hasegawa Y; Ando Y; Ando M; Hashimoto N; Imaizumi K; Shimokata K
Ann N Y Acad Sci; 2006 Nov; 1086():223-32. PubMed ID: 17185519
[TBL] [Abstract][Full Text] [Related]
13. [Late phase II study of irinotecan hydrochloride (CPT-11) in advanced gastric cancer. CPT-11 Gastrointestinal Cancer Study Group].
Futatsuki K; Wakui A; Nakao I; Sakata Y; Kambe M; Shimada Y; Yoshino M; Taguchi T; Ogawa N
Gan To Kagaku Ryoho; 1994 Jun; 21(7):1033-8. PubMed ID: 8210254
[TBL] [Abstract][Full Text] [Related]
14. Irinotecan for metastatic colorectal cancer.
Med Lett Drugs Ther; 1997 Jan; 39(992):8. PubMed ID: 9008684
[No Abstract] [Full Text] [Related]
15. Irinotecan-induced dysarthria: A case report and review of the literature.
Ramirez KG; Koch MD; Edenfield WJ
J Oncol Pharm Pract; 2017 Apr; 23(3):226-230. PubMed ID: 26911479
[TBL] [Abstract][Full Text] [Related]
16. Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer--a randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO).
Thuss-Patience PC; Kretzschmar A; Bichev D; Deist T; Hinke A; Breithaupt K; Dogan Y; Gebauer B; Schumacher G; Reichardt P
Eur J Cancer; 2011 Oct; 47(15):2306-14. PubMed ID: 21742485
[TBL] [Abstract][Full Text] [Related]
17. Thalidomide and irinotecan-associated diarrhea.
Tchekmedyian NS
Am J Clin Oncol; 2002 Jun; 25(3):324. PubMed ID: 12040298
[No Abstract] [Full Text] [Related]
18. Relationship of serum bilirubin to toxicity in patients with metastatic colorectal cancer treated with single-agent high-dose irinotecan.
Kramar A; Gourgou-Bourgade S; Ychou M
J Clin Oncol; 2005 Jan; 23(3):650; author reply 650-1. PubMed ID: 15659517
[No Abstract] [Full Text] [Related]
19. [Clinical activity spectrum of irinotecan].
Cottu PH; Extra JM; Lerebours F; Espie M; Marty M
Bull Cancer; 1998 Dec; Spec No():21-5. PubMed ID: 9932080
[TBL] [Abstract][Full Text] [Related]
20. Irinotecan as maintenance therapy in high-risk hepatoblastoma.
Qayed M; Powell C; Morgan ER; Haugen M; Katzenstein HM
Pediatr Blood Cancer; 2010 May; 54(5):761-3. PubMed ID: 20063426
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
